✦ LIBER ✦

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

✍ Scribed by Glen J. Weiss, Joseph Chao, Jeffrey D. Neidhart, Ramesh K. Ramanathan, Dawn Bassett, James A. Neidhart, Chung Hang J. Choi, Warren Chow, Vincent Chung, Stephen J. Forman, Edward Garmey, Jungyeon Hwang, D. Lynn Kalinoski, Marianna Koczywas, Jeffrey Longmate, Roger J. Melton, Robert Morgan, Jamie Oliver, Joanna J. Peterkin, John L. Ryan, Thomas Schluep, Timothy W. Synold, Przemyslaw Twardowski, Mark E. Davis, Yun Yen…show all 25hide

Book ID: 120966758
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 823 KB
Volume: 31
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-012-9921-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

423 Phase 1 dose escalation, safety and

423 Phase 1 dose escalation, safety and pharmacokinetic study of IT-101 (CRLX101), a novel nanopharmaceutical containing camptothecin, in advanced solid tumor cancer patients

✍ Y. Yen; T. Synold; G.J. Weiss; T. Schluep; J. Ryan 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 82 KB

A Phase I First-in-Human Trial of Bardox

A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas

✍ Hong, D. S.; Kurzrock, R.; Supko, J. G.; He, X.; Naing, A.; Wheler, J.; Lawrence 📂 Article 📅 2012 🏛 American Association for Cancer Research 🌐 English ⚖ 753 KB

Pharmacogenetically driven patient selec

Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas

✍ Shivaani Kummar, Martin E. Gutierrez… 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 264 KB

367 A first-in-human Phase 1 study of an

367 A first-in-human Phase 1 study of anti-CD105 antibody therapy with TRC105 in patients with advanced solid tumors

✍ L. Rosen; M.S. Gordon; H.I. Hurwitz; M.K. Wong; J. Goldman; B.J. Adams; D. Alvar 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

A phase 1b study of humanized KS-interle

A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

✍ Joseph P Connor, Mihaela C Cristea, Nancy L Lewis, Lionel D Lewis… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 456 KB

A first-in-class, first-in-human, phase

A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours

✍ Warso, M A; Richards, J M; Mehta, D; Christov, K; Schaeffer, C; Rae Bressler, L; 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 748 KB